Legend Biotech Corp ADR (NASDAQ:LEGN) price on Wednesday, February 05, fall -0.18% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $37.77.
A look at the stock’s price movement, the close in the last trading session was $37.84, moving within a range at $37.65 and $39.31. The beta value (5-Year monthly) was 0.114. Turning to its 52-week performance, $70.13 and $30.17 were the 52-week high and 52-week low respectively. Overall, LEGN moved 5.56% over the past month.
Legend Biotech Corp ADR’s market cap currently stands at around $6.93 billion, with investors looking forward to this quarter’s earnings report slated for in March.
Analysts have a consensus estimate of 179M for the company’s revenue for the quarter, with a low and high estimate of 160M and 200.78M respectively. The average forecast suggests up to a 125.26% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 616.37M, representing a 116.16% jump on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that LEGN is a 50% Sell. On the other hand, the stock is on average a 50% Sell as suggested by medium term indicators while long term indicators are putting the stock in 100% Sell category.
11 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 0 analyst(s) rate the stock as a Hold, 11 recommend LEGN as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
LEGN’s current price about 7.39% and 3.45% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 58.58, while 7-day volatility ratio is 5.40% and 6.43% in the 30-day chart. Further, Legend Biotech Corp ADR (LEGN) has a beta value of 0.18, and an average true range (ATR) of 2.01. Analysts have given the company’s stock an average 52-week price target of $91, forecast between a low of $83 and high of $94. Looking at the price targets, the low is -119.75% off current price level while to achieve the yearly target high, price needs to move -148.87%. Nonetheless, investors will most likely welcome a -140.93% jump to $91 which is the analysts’ median price.
If we refocus on Legend Biotech Corp ADR (NASDAQ:LEGN), historical trading data shows that trading volumes averaged 1.21 over the past 10 days and 1.50 million over the past 3 months. The company’s latest data on shares outstanding shows there are 183.45 million shares.
The 0.83% of Legend Biotech Corp ADR’s shares are in the hands of company insiders while institutional holders own 49.19% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 13.11 million on 2025-01-15, giving us a short ratio of 9.35. The data shows that as of 2025-01-15 short interest in Legend Biotech Corp ADR (LEGN) stood at 1365.0 of shares outstanding, with shares short falling to 22.95 million registered in 2024-12-13. Current price change has pushed the stock 16.07% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the LEGN stock continues to rise going into the next quarter.
